Insulin resistance impairs viral dynamics independently of ethnicity or genotypes

J Clin Gastroenterol. 2012 Mar;46(3):228-34. doi: 10.1097/MCG.0b013e31822a2dc6.

Abstract

Background and aim: Data concerning the influence of insulin resistance (IR) and ethnicity on early phases of viral kinetics after initiation of peginterferon plus ribavirin in treatment-naive, chronic hepatitis C (CHC) patients are limited.

Methods: A total of 263 nondiabetic CHC patients treated with peginterferon plus ribavirin were enrolled for analysis from an Egyptian and Spanish center. IR was evaluated by homeostasis model assessment (HOMA)-IR. Hepatitis C virus (HCV) RNA levels were measured at baseline, 48 hours, 2, 4, and 12 weeks after treatment initiation. Sustained virological response (SVR) was examined 24 weeks after therapy discontinuation.

Results: Baseline HOMA-IR strongly influenced 48 hours viral dynamics. HCV-RNA decay observed at 48 hours after the first injection of peginterferon was significantly lower (0.91±0.51 log) in patients with HOMA ≥2 compared with those with HOMA <2 (1.8±0.95 log, P=0.005) this effect was independent of stage of liver fibrosis, HCV genotype, and ethnicity. These differences remained with several cutoffs such as HOMA >3 or HOMA >4. Multivariate analysis identified baseline insulin levels as the main independent variable affecting the 48-hour response in addition to baseline HCV-RNA. The difference in early viral kinetics between patients with HOMA ≥2 or <2 is associated with a significant difference in the percentage of patients achieving both rapid virological response and SVR.

Conclusions: IR is a major determinant of the early viral kinetic response to peginterferon plus ribavirin, which has a great impact on subsequent rapid virological response and SVR in CHC patients. This suggests that strategies to improve IR may have a positive effect on SVR and may be early monitored.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • Black People / ethnology
  • Drug Therapy, Combination
  • Egypt
  • Female
  • Genotype
  • Hepacivirus / drug effects*
  • Hepacivirus / genetics*
  • Hepacivirus / physiology
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / ethnology*
  • Hepatitis C, Chronic / genetics
  • Hepatitis C, Chronic / virology
  • Hospitals, University
  • Humans
  • Insulin Resistance*
  • Interferon-alpha / therapeutic use
  • Male
  • Middle Aged
  • Polyethylene Glycols / therapeutic use
  • Ribavirin / therapeutic use
  • Spain
  • Treatment Outcome
  • Viral Load
  • White People / ethnology

Substances

  • Antiviral Agents
  • Interferon-alpha
  • Polyethylene Glycols
  • Ribavirin